HINDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Vyome Holdings, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.84−0.03 (-1.60%)
Close on Oct 19, 2026
- Market cap
- $12.91M
- P/E (TTM)
- –
- Dividend yield
- –
Vyome Holdings, Inc revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical [Member] | $26.96K | $31.59K | $36.55K | $34.63K | $49.95K | $198.58K | $61.43K | $84.53K | – | – | – | – | 100.0% | -46.0% |
| Single reportable segment | – | – | – | – | $1.24M | $1.11M | – | – | $1.97M | $1.94M | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale of products [Member] | $24.82K | $25.47K | $26.25K | $26.97K | $44.70K | $76.73K | $22.15K | $84.13K | – | – | – | – | 92.1% | -44.5% |
| Royalty income related to above product sales [Member] | $2.14K | $6.13K | $10.30K | $7.65K | $5.26K | $4.95K | $39.28K | $397 | – | – | – | – | 7.9% | -59.4% |
| Reshape vest and diabetes bloc-stim neuromodulation products | – | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
| DBSN Device | – | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $0 | – | – |
| Obalon Balloon system | – | – | – | – | – | – | – | $0 | $0 | $0 | – | $0 | – | – |
| Service fee for arrangements for sale of Dandruff products [Member] | – | – | – | – | – | – | $0 | – | – | – | – | – | – | – |
| Licensing and milestone fees Luliconazole [Member] | – | – | $0 | $0 | $0 | $116.90K | – | – | – | – | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | $1.09M | $931.00K | $1.60M | $2.01M | $1.66M | $1.62M | $1.66M | $1.73M | – | – |
| Australia | – | – | – | – | $68.00K | $78.00K | $76.00K | $111.00K | $103.00K | $102.00K | $107.00K | $139.00K | – | – |
| Europe | – | – | – | – | $81.00K | $98.00K | $123.00K | $168.00K | $198.00K | $198.00K | $200.00K | $258.00K | – | – |
| Rest of world | – | – | – | – | $1.00K | $6.00K | $9.00K | $4.00K | $1.00K | $26.00K | $14.00K | $26.00K | – | – |
From the segment and revenue-disaggregation notes of Vyome's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.